U.S. markets closed

Vanda Pharmaceuticals Inc. (VNDA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.09-0.51 (-4.77%)
At close: 4:00PM EDT

9.90 -0.19 (-1.83%)
After hours: 5:15PM EDT

Vanda Pharmaceuticals Inc.

2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
United States
202 734 3400
http://www.vandapharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees284

Key Executives

NameTitlePayExercisedYear Born
Dr. Mihael H. PolymeropoulosFounder, Pres, CEO & Director1.43M1.81M1960
Mr. Timothy WilliamsSr. VP, Gen. Counsel & Sec.599.18kN/A1976
Mr. Gunther BirznieksSr. VP of Bus. Devel.587.14kN/A1969
Mr. Kevin Patrick MoranActing CFO, VP & TreasurerN/AN/A1984
Mr. Aranthan Jones IIChief Corp. Affairs & Communications OfficerN/AN/A1976
Mr. Joakim WijkstromSr. VP & Chief Marketing OfficerN/AN/A1966
Mr. Scott L. HowellChief People OfficerN/AN/AN/A
Ms. Elizabeth Van EveryHead of Corp. AffairsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, and delayed sleep phase disorder; Fanapt® (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Corporate Governance

Vanda Pharmaceuticals Inc.’s ISS Governance QualityScore as of October 6, 2020 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 6; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.